Osteoarthritis – Epidemiology – Epidemiology Data Slicer

launch Related Market Assessment Reports

• Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)

  May 2023

  Immune checkpoint inhibitors continue to dominate the treatment of non-small cell lung cancer (NSCLC), and biomarker-based approaches are increasingly segmenting the space and providing new…

• Osteoporosis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

  May 2023

  A wide array of drugs is available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially…

• Non-Small-Cell Lung Cancer – Geographic Focus: China – Non-Small-Cell Lung Cancer – China In-Depth (China)

  April 2023

  Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably,…

• Crohn’s Disease – Unmet Need – Detailed, Expanded Analysis (US & EU)

  April 2023

  TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’…

• Psoriasis – Current Treatment – Detailed, Expanded Analysis Adult Psoriasis – Treatment Algorithms – Claims Data Analysis (US)

  Adult psoriasis treatment represents an increasingly lucrative market for biologics in the moderate to severe population, in which conventional systemic and topical treatments alone are not…